A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new drug also offers the ability to have its effects reversed quickly.



Over the past five years, two major changes have occurred in cardiovascular information systems (CVIS) and cardiovascular picture archiving and communications systems (PACS). There is a migration from disparate reporting and imaging systems toward a single, unified system. The second trend is easier access to patient information using Web-based and cloud technology.



In this era of financial cost-cutting, questions are raised over the true need for 256- or 320-slice computed tomography (CT) systems for cardiac imaging. There are many radiologists and cardiologists who argue a 64-slice CT system is good enough to make a cardiac diagnosis without spending twice as much for the higher-slice systems.



Advancements in newer 64-slice computed tomography (CT) systems and the introduction of 256- and 320-slice systems are helping to significantly reduce exposure to ionizing radiation.


September 15, 2010 — As the result of a new partnership, the Image-Arena advanced visualization software will be integrated into the Impax cardiovascular picture archiving and communication system (PACS). Agfa HealthCare has signed an agreement with TomTec to add its Image-Arena solution into Agfa's Impax Cardiovascular.

September 15, 2010 – The U.S. Food and Drug Administration (FDA) granted 510(k) market approval for the Medivance noninvasive Arctic Sun 5000 therapeutic temperature management device. The new patient cooling device offers fast initiation of treatment, simple programming capabilities and easy access to treatment.

September 15, 2010 – A study evaluating the level of platelet aggregation achieved after switching from clopidogrel (Plavix) 75 mg once-daily maintenance dosing plus aspirin to prasugrel (Effient) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

September 15, 2010 – The U.S. Food and Drug Administration (FDA) has extended the time to complete its review of the new drug application (NDA) for ticagrelor (Brilinta), which is the first reversible oral antiplatelet drug.

September 15, 2010 – A high-definition intravascular ultrasound (IVUS) system will be demonstrated during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium Sept. 21-25 in Washington, D.C.


September 14, 2010 – Transcatheter valves, drug-eluting balloons and the latest stent comparison trial data are among the top three trends at Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific sessions Sept. 21-25 in Washington, D.C.


Subscribe Now